Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05912374 · ClinicalTrials.gov registry record · NA
Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs
A NA study, sponsored by University of Connecticut.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT05912374: Completed NA study, sponsored by University of Connecticut.
NCT05912374 is a NA study that has completed, run by University of Connecticut. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05912374, a NA study, has completed, sponsored by University of Connecticut.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goal of this pilot work was to determine if the cognitive dysfunction accommodation strategies help patients retain/utilize more HIV prevention information and increase PrEP adherence. Fifty people who inject drugs (PWID) were prescribed PrEP and randomized to one of two conditions, Twenty-five PWID participated in a standard HIV prevention session and 25 other PWID participated in a HIV prevention session with the included accommodation strategies. At recruitment participants were asked to provide self-report of the screening form and cognitive functioning. The intervention consisted of a total of 5 sessions: 1 meeting to gain baseline information of participants and 4 intervention sessions. Participants completed the consent form, demographics, skills assessment, drug use behavior assessment, and HIV risk behavior assessment at the pre-interview meeting. Participants completed PrEP uptake assessments and skills assessments immediately following the intervention to compare the pre/post results between the two groups. All participants also completed an acceptability rating to help researchers determine the acceptability of the accommodation strategies used, at the end of the 4th session. The objective was to determine if the proposed accommodation strategies are feasible and efficacious at improving HIV prevention outcomes, including knowledge and skills. Information gleaned from this process will be used to refine the intervention approach for future testing and implementation.
Primary Outcome
a 15 item checklist of HIV risk reduction skills, the lower the score the lower the ability to perform HIV risk reduction skills
Interventions
- BEHAVIORAL standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
- BEHAVIORAL enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2022-12-12 |
| Phase | NA |
What the finished NCT05912374 record still lists
NCT05912374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB) is the first listed.
NCT05912374 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05912374 about?
NCT05912374 is a clinical study titled "Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs". The goal of this pilot work was to determine if the cognitive dysfunction accommodation strategies help patients retain/utilize more HIV prevention information and increase PrEP adherence. Fifty people who inject drugs (PWID) were prescribed PrEP and randomized to one of two conditions, Twenty-five ...
What is the current status of trial NCT05912374?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2022-09-07. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT05912374?
The interventions under investigation include: standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB) (BEHAVIORAL), enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05912374?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05912374's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI